American Journal of Cardiology
Volume 103, Issue 6 , Pages 824-828 , 15 March 2009

Relation of Bisphosphonate Therapies and Risk of Developing Atrial Fibrillation

  • T. Jared Bunch, MD

      Affiliations

    • Intermountain Heart Rhythm Specialists, Intermountain Medical Center, Murray, Utah
    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • Corresponding Author InformationCorresponding author: Fax: 801-507-3584
    • ,
  • Jeffrey L. Anderson, MD

      Affiliations

    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • University of Utah, Salt Lake City, Utah
    • ,
  • Heidi T. May, MSPH

      Affiliations

    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • ,
  • Joseph B. Muhlestein, MD

      Affiliations

    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • University of Utah, Salt Lake City, Utah
    • ,
  • Benjamin D. Horne, PhD, MPH

      Affiliations

    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • University of Utah, Salt Lake City, Utah
    • ,
  • Brian G. Crandall, MD

      Affiliations

    • Intermountain Heart Rhythm Specialists, Intermountain Medical Center, Murray, Utah
    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • ,
  • J. Peter Weiss, MD

      Affiliations

    • Intermountain Heart Rhythm Specialists, Intermountain Medical Center, Murray, Utah
    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • ,
  • Donald L. Lappé, MD

      Affiliations

    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • ,
  • Jeffrey S. Osborn, MD

      Affiliations

    • Intermountain Heart Rhythm Specialists, Intermountain Medical Center, Murray, Utah
    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • ,
  • John D. Day, MD

      Affiliations

    • Intermountain Heart Rhythm Specialists, Intermountain Medical Center, Murray, Utah
    • Department of Cardiology, Intermountain Medical Center, Murray, Utah

Received 1 October 2008 ,Revised 20 November 2008 ,Accepted 20 November 2008.

References 

  1. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822
  2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures (Fracture Intervention Trial Research Group). Lancet. 1996;348:1535–1541
  3. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082
  4. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women (Hip Intervention Program Study Group). N Engl J Med. 2001;344:333–340
  5. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial (Vertebral Efficacy With Risedronate Therapy (VERT) Study Group). JAMA. 1999;282:1344–1352
  6. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653–661
  7. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809
  8. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356:1895–1896
  9. Early communication of an ongoing safety review (Bisphosphonates: alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel w/calcium), tiludronate (Skelid), and zoledronic acid (Reclast, Zometa)). http://www.fda.gov/Cder/Drug/early_comm/bisphosphonates.htmAccessed March 13, 2008
  10. Sørensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case–control study. BMJ. 2008;336:813–816
  11. Stafford RS, Drieling RL, Hersh AL. National trends in osteoporosis visits and osteoporosis treatment, 1988–2003. Arch Intern Med. 2004;164:1525–1530
  12. Marcovitz PA, Tran HH, Franklin BA, O'Neill WW, Yerkey M, Boura J, et al. Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol. 2005;96:1059–1063
  13. von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999;106:273–278
  14. Jorgensen L, Engstad T, Jacobsen BK. Bone mineral density in acute stroke patients: low bone mineral density may predict first stroke in women. Stroke. 2001;32:47–51
  15. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials (Studies of Left Ventricular Dysfunction). J Am Coll Cardiol. 1998;32:695–703
  16. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries). J Am Coll Cardiol. 1997;30:406–413
  17. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J. 2000;140:878–885
  18. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476–484

PII: S0002-9149(08)02092-4

doi: 10.1016/j.amjcard.2008.11.037

American Journal of Cardiology
Volume 103, Issue 6 , Pages 824-828 , 15 March 2009

Article Tools

* Image Usage & Resolution